Consider a group like this. Marcus Elder runs twelve locations across central Ohio, and in the same month two buyers came calling. One introduced itself as a DSO partner. The other was a sponsor looking for a platform. Marcus asked both the same question, what happens to my associates, and got two answers that sounded nearly identical and meant opposite things. A pattern that appears across the data: the operators who get blindsided after close are rarely the ones who negotiated badly, they are the ones who never asked what the buyer intended to do with what they bought. Marcus's own visibility audit had come back at 38 out of 100. If you have never checked what this looks like in your own practice, you are standing where they stood.
The letter of intent on your desk uses the word partnership in the first paragraph. So did the other one. Two buyers, two structures, two very different sets of intentions for the group you spent eleven years assembling, and both of them reached for the same vocabulary. You are not confused about the money. You can read a multiple, you can model a rollover, you can price a hold-back. What you cannot read from the term sheet is what your Tuesday looks like eighteen months after close, who your associates actually answer to, and whether the thing that made your locations profitable in the first place survives contact with a new owner. That is the difference worth understanding before anyone signs.
Why do two offers for the same group look nothing alike?
Consolidation now accounts for roughly 32% of the market, and the buyers sitting inside that number are not one species. A DSO acquiring your twelve locations is buying operating capacity: chairs, providers, patient volume it can fold into a support structure it already runs. A private equity sponsor acquiring a dental group is buying the platform itself, the thing that acquires. One wants your practices. The other wants your ability to keep buying practices. Across 201,000+ US practices and a $179.4B market, that single distinction shapes almost everything about your post-close life. Your group either becomes a set of locations inside somebody else's system, or the vehicle through which the next forty locations arrive. Read the document again with that question in front of you: is the buyer describing what they will do with your offices, or what they will do with your leadership? The first is an operating acquisition. The second is a platform investment. The economics can look nearly identical on the page. The next five years will not feel remotely the same.
What is a DSO actually buying when it buys your locations?
It is buying same-store performance and the belief that it can improve it. Everything a DSO does after close points one direction: more production per chair, less cost per location, tighter systems across the group. That is not a criticism, it is the model working as designed. The audit puts unrealised demand at $147K for the average solo practice, and when you run a figure like that across a twelve-location group, you begin to see what the buyer sees when they look at your schedule. They are not buying your ceiling. They are buying the distance between where you are and where the systems say you could be. Your role in that story is usually transitional. You are valuable during integration because you hold the relationships, the local reputation and the knowledge of which associate can be trusted with which case. Once those transfer, the platform does not need a founder, it needs a regional director. Most operators know this intellectually. Very few have felt it before it happens.
What is a private equity sponsor actually buying?
A sponsor is buying an asset it intends to sell. That sentence is not cynical, it is simply the mandate, and understanding it removes most of the surprise from what follows. When a fund takes a position in dental, it is underwriting a thesis: this platform can add locations faster than the market, integrate them without breaking the clinical product, and be worth more to a larger buyer in three to seven years. Your leadership team is part of the asset. Your acquisition pipeline is part of the asset. Your ability to say yes to a deal in ninety days is part of the asset. Consolidation has already absorbed about a third of the market, which means the easy geography is gone and the returns increasingly have to come from performance rather than pace. Your practice group will be measured on how well it makes the next acquisition perform, not just on how well it performs itself. That is a fundamentally different job than the one you have been doing.
How does the hold period change what happens after close?
A DSO with an indefinite operating horizon can afford to integrate you slowly. A sponsor with a fund clock cannot. Every decision inside a private equity backed platform gets reverse-engineered from an eventual sale date, and that shows up in ways nobody writes into the LOI. Reporting gets heavier because the story has to be legible to the next buyer. Capital gets allocated toward whatever compounds inside the window rather than whatever compounds eventually. Initiatives that take four years to prove out struggle to get funded in year five of a seven year hold. You will feel this most acutely in patient discovery and reputation work, where the returns are real but rarely instant. If your locations are already visible, that clock works in your favour, because you are compounding from a position of strength. If they are not, the clock becomes the reason nobody funds fixing it. Ask directly where the buyer is in its own fund life. The answer tells you more about your next three years than any org chart will.
What really happens to clinical autonomy after the paperwork?
Autonomy erodes through defaults, not decrees. No buyer sends a memo telling you how to treatment plan. What arrives instead is a preferred lab, a standard implant system, a scheduling template that assumes a certain number of hygiene columns, and a materials contract that quietly makes your preferred composite the expensive choice. Each one is defensible. Together they redraw the edges of clinical judgement in your practices. The pattern differs by model in degree rather than in kind. Operating DSOs standardise because standardisation is the product they sell. Sponsor-backed platforms standardise because consistency is what makes the group legible to the next buyer. Your associates will notice within two quarters, and the ones with options will start taking calls. The protective factor is not a clause, it is clarity: whether clinical decision rights were named specifically at signing, in writing, at the case level. Vague language about respecting clinical independence has protected almost nobody. Specific language about who selects materials, who sets appointment lengths and who approves a treatment plan protects almost everybody.
What does your team's daily experience look like after a DSO close?
The first ninety days are usually calmer than your staff fears and the following year is usually harder than you promise. Payroll systems change. Benefits change, sometimes upward. Someone from a regional office starts attending huddles. The front desk gets a new phone script and a new set of metrics, and the person who has run that desk for nine years discovers her judgement is now an input rather than the decision. Meanwhile 33.9% of practices are actively recruiting hygienists, which means your team has a live market for their skills and knows it. Your retention risk in year one is not compensation, it is the loss of being consulted. Teams accept enormous operational change when someone explains the reasoning. They leave over small changes imposed without explanation. If you are staying through integration, that translation work is the single most valuable thing you will do, and it is almost never written into your employment agreement or valued in the purchase price.
What changes for staff under a private equity backed platform?
The texture is different. Sponsor-backed groups tend to invest earlier and harder in infrastructure, because infrastructure is what makes a platform saleable, so your team may see better systems, better technology and clearer career ladders than a slower operating buyer would fund. What comes with it is velocity. New locations arrive on a schedule set by a deal pipeline rather than by operational readiness, and the people absorbing that pace are your office managers and lead clinicians. Turnover in those roles is the failure mode to watch, because they are the ones holding local patient relationships together while everything above them reorganises. There is a second dynamic worth naming. When a sale approaches, the organisation tightens. Discretionary spending gets examined, headcount decisions get deferred, and staff can sense the shift long before anyone announces anything. Your best people will interpret that uncertainty through whatever trust you have built with them. That trust is an asset nobody diligences and every operator eventually needs.
One buyer wants your practices. The other wants your ability to keep buying practices. Everything that happens to you after close follows from which one is sitting across the table.
Why is multiple compression rewriting your exit math?
The arbitrage that powered a decade of dental roll-ups was simple: buy small at a modest multiple, sell the assembled group at a much larger one. That spread has narrowed. As consolidation moved through roughly a third of the market, the supply of clean, well-run, unclaimed groups thinned out, and buyers responded by underwriting more carefully rather than paying more freely. What they scrutinise now is the quality of the demand underneath the revenue. Where do new patients originate. Is that source repeatable. Does it survive a change of ownership. This is where a lot of otherwise healthy groups take a haircut. If your growth story is entirely acquisitive, you are selling arithmetic, and arithmetic can be bought anywhere. If you can document organic patient demand across your locations, you are selling an engine. Implant demand is growing 8.5% a year at an average case value of $4,500, cosmetic 6.8% at $3,800, ortho 5.1% at $5,500. Your group either captures that growth in its own market or watches it route to whoever is visible.
| What buyers now diligence | Group with positioning clarity | Group without it |
|---|---|---|
| Visibility in AI-assisted search | Named in answers, inside the 30% of practices the engines can actually see | Sits within the 70% of practices invisible to AI systems |
| Readiness score across locations | Above 65, the top 8% band nationally | Below 40, the national average |
| Map and directory behaviour | Complete profiles earning up to 7x more clicks | Loses share of the 82% of searches that end in a Maps interaction |
| High-value case mix | AI-referred patients booking high-value treatment at 2-3x the rate | Implant, cosmetic and ortho growth captured by a competing group |
| Growth narrative at exit | Documented organic demand, repeatable after ownership change | Growth rests on acquisition pace alone |
The Dental Index national practice audit · 2026
Which model actually protects the patient flow you sold them?
Neither, automatically. This is the part operators consistently get wrong. Both buyer types assume patient volume is a property of the practices they purchased, and both discover otherwise when demand shifts underneath them. There are 432,000 dental searches a month running through AI systems, and the systems answering those searches can only name practices they can read. The Dental Index national practice audit found that 70% of practices are effectively invisible to them. If your locations are in that group, you did not sell a durable patient pipeline, you sold a historical one, and whoever owns it next will find that out on their schedule rather than yours. Average readiness across the country sits below 40 out of 100, with only 8% of practices scoring above 65. Your twelve locations are almost certainly not uniform on this measure, and the variance itself is diligence material. Understanding dental practice acquisition from the buyer's side means understanding that they are increasingly pricing the durability of your demand, not just its history.
The structure is not the story
Operators spend diligence arguing about entity structure and rollover percentages, then spend the next two years living inside a culture nobody negotiated. The groups that come through a close intact understood early that the buyer's intention, hold it or resell it, predicts the daily experience far better than the legal form does.
Demand is an asset, not a byproduct
Most groups treat patient flow as something that happens because the practices are good. Buyers have stopped accepting that. The operators who price well now think of visibility the way they think of real estate or equipment: a documented asset that shows up in the valuation, or a quiet liability that surfaces in the data room.
Autonomy is written, not assumed
Nobody loses clinical control in a single moment. It goes in defaults, contracts and templates, each one reasonable on its own. The groups that keep it did not fight harder after close, they simply named the specific decisions that stayed with clinicians before the ink dried.
Your second exit starts on day one
Rollover equity gets treated as a lottery ticket resolved by market conditions. The operators who do well on the second bite treated it as something they were building from close: traceable demand, stable clinicians, consistent locations. None of that can be assembled in the twelve months before a sale.
What does the second bite of the apple really depend on?
Rollover equity is the reason most operators say yes to a sponsor-backed deal, and it is worth exactly what the next buyer decides to pay. That valuation will hinge on things largely outside a single operator's control, and on a small number of things very much inside it. Consider what actually travels well to a subsequent buyer:
- Demand you can trace. A patient source you can name, measure and repeat is worth more than the same revenue with an unexplained origin.
- Case mix quality. Patients arriving through AI-assisted discovery book high-value treatment at 2-3x the rate, which changes the profile of the revenue, not only its size.
- Clinical stability. Associate tenure is read as a proxy for whether the platform can absorb the next acquisition without breaking.
- Location-level consistency. Wide variance across sites signals integration risk and gets priced accordingly.
None of that is built in the final year before a sale. You either compound it from close or you explain its absence later, and explanations do not carry a multiple.
What should you be measuring before anything gets signed?
Before valuation, before structure, before the culture conversation with the buyer's operating partner, measure what you are actually bringing to the table. Most groups arrive at diligence with financial clarity and total darkness on demand. You know production per provider by location and have no idea which of those locations a patient can find when they ask an AI system for an implant provider near them. That asymmetry is expensive. Practices with complete profile signals earn up to 7x more clicks, and 82% of searches end in a Maps interaction. Your group either shows up at that moment across all twelve markets or it does not, and the answer differs site by site more than most operators expect. Run the diagnostic before the buyer does. If the picture is strong, it becomes leverage in a negotiation where you currently have little. If it is weak, you would rather learn it now, while you still control the timeline, than watch it surface in a data room as a reason to retrade the price.
Marcus took the sponsor deal. Not because the number was higher, it was not by much, but because he asked the second question and got a straight answer about the hold period. Then he did the thing almost nobody does before close. He measured where his twelve locations actually appeared when patients went looking, and found four of them essentially unfindable. He fixed those four first. That work is the same work that makes a group legible to a buyer, and it starts from the same place: knowing what a patient sees. Positioning clarity is not a separate project from your exit. It is the difference between selling a story about demand and selling demand itself, and you can see which one you have this week, from the national practice audit data, before anyone else does.